Cefoperazone


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : IV/IM 2-4 g/day in 2 divided doses, up to 12 g/day for severe infections.
Dosage Details
Parenteral
Susceptible infections
Adult: As sodium: 2-4 g daily in 2 divided doses, increased to 12 g daily in 2-4 divided doses for severe infections given as deep IM or IV infusion.
Renal Impairment
W/ hepatic impairment: 1-2 g daily.
Hepatic Impairment
Max for hepatic impairment or biliary obstruction: 4 g daily. W/ renal impairment: 1-2 g daily.
Contraindications
Hypersensitivity to cephalosporin.
Special Precautions
History of penicillin allergy; renal or hepatic impairment; pregnancy, lactation; cystic fibrosis.
Adverse Reactions
Skin rash, urticaria; eosinophilia, diarrhoea, nausea, vomiting; phloebitis; hypoprothrombinaemia; superinfection.
Potentially Fatal: Neuromuscular hypersensitivity; nephrotoxicity.
IM/IV/Parenteral: B
Drug Interactions
Disulfiram-like reaction with alcohol. Potentiates anticoagulants.
Potentially Fatal: Enhances nephrotoxicity by aminoglycosides and furosemide.
Action
Description: Cefoperazone binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Distribution: Widely distributed into body tissues and fluids; poor CSF penetration. Crosses the placenta and enters breast milk (low concentrations); bile (high concentrations). Protein-binding: 82-93%
Excretion: Mainly via the bile. Via the urine within 12-24 hrs by glomerular filtration (30% as unchanged); proportion may be increased in hepatic or biliary disease.
Storage
Store below 25°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefoperazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in